RU2016105310A - Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора - Google Patents
Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора Download PDFInfo
- Publication number
- RU2016105310A RU2016105310A RU2016105310A RU2016105310A RU2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- mediated
- formula
- disorders
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (8)
1. Соединение формулы (I), где соединение представляет собой (5R)-N5-(1-(n-толил)циклопропил)-(6R)-N6-(2-(4-метилпиперазин-1-ил)этил)-(4S,7R)-[4,7-этилен-спиро[2.4]гептан]-5,6-дикарбоксамид;
или соль соединения.
2. Соединение формулы (I) по п. 1, или его фармацевтически приемлемая соль, для применения в качестве лекарственного средства.
3. Фармацевтическая композиция, которая содержит, в качестве активного компонента, соединение формулы (I) по п. 1, или его фармацевтически приемлемую соль, и по меньшей мере один терапевтически инертный наполнитель.
4. Применение соединения формулы (I) по п. 1, или его фармацевтически приемлемой соли, для приготовления лекарственного средства для предотвращения или лечения заболевания, выбранного из воспалительных заболеваний, обструктивных заболеваний дыхательных путей, аллергических состояний, ВИЧ-опосредованных ретровирусных инфекций, сердечно-сосудистых нарушений, нейровоспаления, неврологических нарушений, боли, заболеваний, опосредованных прионами и нарушений, опосредованных амилоидом; и для модуляции иммунных ответов.
5. Соединение формулы (I) по п. 1, или его фармацевтически приемлемая соль, для применения для предотвращения или
лечения заболевания, выбранного из воспалительных заболеваний, обструктивных заболеваний дыхательных путей, аллергических состояний, ВИЧ-опосредованных ретровирусных инфекций, сердечно-сосудистых нарушений, нейровоспаления, неврологических нарушений, боли, заболеваний, опосредованных прионами и нарушений, опосредованных амилоидом; и для модуляции иммунных ответов.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2013055906 | 2013-07-18 | ||
IBPCT/IB2013/055906 | 2013-07-18 | ||
PCT/EP2014/065351 WO2015007830A1 (en) | 2013-07-18 | 2014-07-17 | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2016105310A true RU2016105310A (ru) | 2017-08-23 |
Family
ID=51205401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016105310A RU2016105310A (ru) | 2013-07-18 | 2014-07-17 | Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора |
Country Status (13)
Country | Link |
---|---|
US (1) | US9533964B2 (ru) |
EP (1) | EP3022188B1 (ru) |
JP (1) | JP6330038B2 (ru) |
KR (1) | KR20160033747A (ru) |
CN (1) | CN105377824B (ru) |
AU (1) | AU2014292064B2 (ru) |
BR (1) | BR112016001106A8 (ru) |
CA (1) | CA2915757A1 (ru) |
ES (1) | ES2639798T3 (ru) |
MX (1) | MX360699B (ru) |
RU (1) | RU2016105310A (ru) |
TW (1) | TW201536289A (ru) |
WO (1) | WO2015007830A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3022188B1 (en) | 2013-07-18 | 2017-06-07 | Actelion Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
BR112016025659B1 (pt) | 2014-05-13 | 2023-03-07 | Novartis Ag | Indutores de condrogênese, seu uso, e composição farmacêutica |
ES2791340T3 (es) | 2015-05-27 | 2020-11-03 | Kyorin Seiyaku Kk | Derivado de urea o sal farmacológicamente aceptable del mismo |
CN107849049B (zh) | 2015-05-27 | 2021-03-16 | 杏林制药株式会社 | 脲衍生物或其药用盐 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686454A (en) | 1993-07-16 | 1997-11-11 | Merck & Co., Inc. | Camphorcarbonyl |
WO2001057074A1 (en) | 2000-02-04 | 2001-08-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection |
US20050164305A1 (en) | 2002-04-03 | 2005-07-28 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
AU2004290368A1 (en) | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
ATE520689T1 (de) | 2007-12-18 | 2011-09-15 | Actelion Pharmaceuticals Ltd | Aminotriazolderivate als alx-agonisten |
WO2010134014A1 (en) * | 2009-05-18 | 2010-11-25 | Actelion Pharmaceuticals Ltd | Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists |
NZ597453A (en) | 2009-06-09 | 2013-03-28 | Actelion Pharmaceuticals Ltd | Fluorinated aminotriazole derivatives as alxr agonists |
US8674111B2 (en) | 2009-06-12 | 2014-03-18 | Actelion Pharmaceuticals Ltd. | Oxazole and thiazole derivatives as ALX receptor agonists |
EP2585054A1 (en) * | 2010-06-24 | 2013-05-01 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
ES2553635T3 (es) * | 2010-11-17 | 2015-12-10 | Actelion Pharmaceuticals Ltd. | Derivados de éster spiro[2.4]heptano puenteados |
AR084172A1 (es) | 2010-12-07 | 2013-04-24 | Actelion Pharmaceuticals Ltd | Derivados aminotriazol hidroxilados como agonistas del receptor alx |
AR084173A1 (es) | 2010-12-07 | 2013-04-24 | Actelion Pharmaceuticals Ltd | Derivados oxazolil-metileter como agonistas del receptor alx |
WO2013009543A1 (en) | 2011-07-11 | 2013-01-17 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
MA37618B1 (fr) * | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
CN104284887B (zh) * | 2012-05-16 | 2016-06-22 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物 |
CA2898301C (en) | 2013-03-06 | 2021-11-16 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
CN105007908B (zh) | 2013-03-06 | 2017-10-03 | 阿勒根公司 | 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途 |
EP3022188B1 (en) | 2013-07-18 | 2017-06-07 | Actelion Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
-
2014
- 2014-07-17 EP EP14739472.0A patent/EP3022188B1/en not_active Not-in-force
- 2014-07-17 AU AU2014292064A patent/AU2014292064B2/en not_active Ceased
- 2014-07-17 TW TW103124607A patent/TW201536289A/zh unknown
- 2014-07-17 RU RU2016105310A patent/RU2016105310A/ru unknown
- 2014-07-17 MX MX2016000731A patent/MX360699B/es active IP Right Grant
- 2014-07-17 BR BR112016001106A patent/BR112016001106A8/pt not_active IP Right Cessation
- 2014-07-17 KR KR1020167004127A patent/KR20160033747A/ko not_active Application Discontinuation
- 2014-07-17 JP JP2016526635A patent/JP6330038B2/ja not_active Expired - Fee Related
- 2014-07-17 US US14/905,768 patent/US9533964B2/en not_active Expired - Fee Related
- 2014-07-17 WO PCT/EP2014/065351 patent/WO2015007830A1/en active Application Filing
- 2014-07-17 CA CA2915757A patent/CA2915757A1/en not_active Abandoned
- 2014-07-17 CN CN201480039969.8A patent/CN105377824B/zh not_active Expired - Fee Related
- 2014-07-17 ES ES14739472.0T patent/ES2639798T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014292064A1 (en) | 2016-03-03 |
MX2016000731A (es) | 2016-04-13 |
BR112016001106A2 (ru) | 2017-07-25 |
US9533964B2 (en) | 2017-01-03 |
EP3022188B1 (en) | 2017-06-07 |
BR112016001106A8 (pt) | 2017-12-26 |
CN105377824B (zh) | 2017-08-04 |
EP3022188A1 (en) | 2016-05-25 |
KR20160033747A (ko) | 2016-03-28 |
TW201536289A (zh) | 2015-10-01 |
JP6330038B2 (ja) | 2018-05-23 |
AU2014292064B2 (en) | 2018-07-05 |
MX360699B (es) | 2018-11-14 |
US20160152584A1 (en) | 2016-06-02 |
CA2915757A1 (en) | 2015-01-22 |
JP2016525107A (ja) | 2016-08-22 |
ES2639798T3 (es) | 2017-10-30 |
WO2015007830A1 (en) | 2015-01-22 |
CN105377824A (zh) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016105310A (ru) | Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора | |
ES2683355T3 (es) | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades | |
MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
HRP20171848T1 (hr) | Upotreba malononitrilamida za neuropatsku bol | |
JP2005538099A5 (ru) | ||
JP2013512903A5 (ru) | ||
RU2006130000A (ru) | Органические соединения | |
RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
JP2016517857A5 (ru) | ||
EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
AR067326A1 (es) | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido | |
HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
RU2016102059A (ru) | Дифторэтил-оксазол замещенные мостиковые производные спиро-[2,4] гептана в качестве агонистов alх рецептора | |
EA201992162A1 (ru) | Составы на основе нирапариба | |
HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
RU2014106611A (ru) | Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора | |
RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
JP2015522018A5 (ru) | ||
RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
PH12019500597A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
JP2017525721A (ja) | 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品 | |
HRP20191869T1 (hr) | Fluoroindol derivati kao pozitivni alosterički modulatori muskarinskog m1 receptora | |
EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
RU2019111873A (ru) | Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм |